ストックスクリーナーアプリを入手
1.72
5.52%
0.09
アフターアワーズ：
1.71
-0.01
-0.58%
前日終値:
$1.63
開ける：
$1.65
24時間の取引高:
491.73K
Relative Volume:
0.94
時価総額：
$181.22M
収益：
$17.91M
当期純損益:
$-47.66M
株価収益率:
-3.7835
EPS:
-0.4546
ネットキャッシュフロー:
$-62.63M
1週間 パフォーマンス:
+11.69%
1か月 パフォーマンス:
-4.97%
6か月 パフォーマンス:
-22.17%
1年 パフォーマンス:
+10.26%
1日の値動き範囲:
$1.565
$1.72
1週間の範囲:
$1.52
$1.72
52週間の値動き範囲:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.72 | 171.74M | 17.91M | -47.66M | -62.63M | -0.4546 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | Oppenheimer | Outperform |
| 2025-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-10 | アップグレード | Citigroup | Neutral → Buy |
| 2025-01-10 | 開始されました | Oppenheimer | Outperform |
| 2024-10-29 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-02-11 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | ダウングレード | Stifel | Buy → Hold |
| 2022-02-01 | 開始されました | Raymond James | Strong Buy |
| 2021-05-03 | 開始されました | Stifel | Buy |
| 2021-03-25 | 繰り返されました | Citigroup | Buy |
| 2020-11-03 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-12-19 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-11-15 | 開始されました | Citigroup | Buy |
| 2018-09-19 | 開始されました | Evercore ISI | Outperform |
| 2017-09-26 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-06-20 | 開始されました | Chardan Capital Markets | Neutral |
| 2014-10-15 | 開始されました | Deutsche Bank | Buy |
| 2014-10-13 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Proqr Therapeutics N V (PRQR) 最新ニュース
MSN Money - MSN
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 - markets.businessinsider.com
ProQR Therapeutics NV expected to post a loss of 12 cents a shareEarnings Preview - TradingView
ProQR Therapeutics N : AGM 2026 POA Registered Shareholders - marketscreener.com
ProQR sets June 2 shareholder meeting, posts agenda documents online - Stock Titan
ProQR (PRQR) 2026 AGM to expand share capital, issuance and buyback powers - Stock Titan
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase - The Globe and Mail
ProQR nominates Boehringer Ingelheim executive to board - Investing.com UK
ProQR nominates Boehringer Ingelheim executive to board By Investing.com - Investing.com Australia
Boehringer exec tapped for ProQR (NASDAQ: PRQR) board nomination - Stock Titan
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors - GlobeNewswire
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Down 24.4% in April - MarketBeat
ProQR Therapeutics NV (MEX:PRQRN) Stock News, Headlines & Updates - GuruFocus
ProQR Therapeutics NV (MEX:PRQRN) Stock Price & 30 Year Financial Data - GuruFocus
Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation - MSN
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
ProQR Therapeutics NV (MEX:PRQRN) Short-term investments - GuruFocus
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR Therapeutics NV (MEX:PRQRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Bart Filius Net Worth (2026) - GuruFocus
De Boer Daniel Anton Net Worth (2026) - GuruFocus
ProQR Therapeutics N.V. (PRQR) - Minichart
Jobs Data: Can ProQR Therapeutics NV withstand a market correctionQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
Stock Analysis: Can ProQR Therapeutics NV outperform under higher oil prices2026 Short Interest & Precise Trade Entry Recommendations - baoquankhu1.vn
Volume Report: Is ProQR Therapeutics NV currently under institutional pressure2026 Gainers & Expert Verified Movement Alerts - baoquankhu1.vn
If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan
ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha
PRQR: Chardan Capital Maintains Buy Rating with $4.00 Price Targ - GuruFocus
Proqr Therapeutics expands early-stage pipeline - BioWorld News
ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital - MarketBeat
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter - Defense World
Aberdeen Group Boosts Stake in ProQR Therapeutics - National Today
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR - MarketBeat
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs - The Globe and Mail
ProQR (PRQR) Partners with Ginkgo Bioworks to Boost AI-Driven Dr - GuruFocus
ProQR partners with Ginkgo on AI drug discovery platform By Investing.com - Investing.com Australia
ProQR updates RNA editing pipeline, targets biliary atresia By Investing.com - Investing.com Australia
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks - Intellectia AI
ProQR updates RNA editing pipeline, targets biliary atresia - Investing.com
Pipeline expansion and cash runway into 2027 for ProQR (PRQR) - Stock Titan
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event - Weekly Voice
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst CallSlideshow (NASDAQ:PRQR) 2026-04-08 - Seeking Alpha
Proqr Therapeutics N V (PRQR) 財務データ
収益
当期純利益
現金流量
EPS
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):